Consistently, treatment of 4T1.2 and MCF-7 cells with LRP5-overexpressing osteocyte-derived CM also produced robust anti-tumor effects, further validating our previous observations (Supplementary Figure S2). This evidence concerns the gene LRP5 and neoplasm.